ES2150404T1 - Composiciones farmaceuticas de tizoxanida y nitozoxanida. - Google Patents

Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Info

Publication number
ES2150404T1
ES2150404T1 ES98920285T ES98920285T ES2150404T1 ES 2150404 T1 ES2150404 T1 ES 2150404T1 ES 98920285 T ES98920285 T ES 98920285T ES 98920285 T ES98920285 T ES 98920285T ES 2150404 T1 ES2150404 T1 ES 2150404T1
Authority
ES
Spain
Prior art keywords
nitozoxanide
tizoxanide
pharmaceutical compositions
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES98920285T
Other languages
English (en)
Other versions
ES2150404T3 (es
Inventor
Jean-Francois Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150404(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/852,447 external-priority patent/US5968961A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of ES2150404T1 publication Critical patent/ES2150404T1/es
Application granted granted Critical
Publication of ES2150404T3 publication Critical patent/ES2150404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para administración oral caracterizada porque comprende como agente activo al menos un compuesto seleccionado del grupo integrado por: el compuesto de fórmula (I) y el compuesto de la fórmula (II).
ES98920285T 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y nitozoxanida. Expired - Lifetime ES2150404T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (2)

Publication Number Publication Date
ES2150404T1 true ES2150404T1 (es) 2000-12-01
ES2150404T3 ES2150404T3 (es) 2003-07-01

Family

ID=27420362

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02002887T Expired - Lifetime ES2232687T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.
ES98920285T Expired - Lifetime ES2150404T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02002887T Expired - Lifetime ES2232687T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.

Country Status (34)

Country Link
EP (2) EP1005342B1 (es)
JP (1) JP3739802B2 (es)
KR (2) KR100426657B1 (es)
CN (2) CN1158074C (es)
AP (1) AP1103A (es)
AR (1) AR057242A2 (es)
AT (2) ATE281166T1 (es)
AU (1) AU740022B2 (es)
BG (2) BG109365A (es)
BR (1) BR9808722A (es)
CA (2) CA2418634C (es)
CZ (2) CZ298270B6 (es)
DE (2) DE69827417T2 (es)
DK (2) DK1222921T3 (es)
EA (2) EA002908B1 (es)
EE (1) EE04870B1 (es)
ES (2) ES2232687T3 (es)
GE (1) GEP20032970B (es)
HU (1) HU229641B1 (es)
IL (2) IL155799A (es)
IS (1) IS2087B (es)
LV (1) LV12492B (es)
ME (1) ME00530B (es)
NO (2) NO313983B1 (es)
NZ (2) NZ513881A (es)
OA (1) OA11169A (es)
PL (1) PL193275B1 (es)
PT (2) PT1005342E (es)
RO (1) RO120605B1 (es)
SI (1) SI20149B (es)
SK (2) SK283947B6 (es)
TR (1) TR199902733T2 (es)
UA (2) UA57079C2 (es)
WO (1) WO1998050035A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US8524278B2 (en) * 2009-02-13 2013-09-03 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide
PE20121118A1 (es) 2009-05-12 2012-09-05 Romark Lab Lc Compuestos de haloalquil heteroaril benzamida
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
CN107105660A (zh) * 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
CN111971292B (zh) 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
PT1005342E (pt) 2003-02-28
KR20040004544A (ko) 2004-01-13
DK1222921T3 (da) 2005-03-07
DE69827417D1 (de) 2004-12-09
IL132516A0 (en) 2001-03-19
CN100515420C (zh) 2009-07-22
EP1005342B1 (en) 2002-12-04
EA002908B1 (ru) 2002-10-31
EP1222921B1 (en) 2004-11-03
ES2232687T3 (es) 2005-06-01
NO313983B1 (no) 2003-01-13
CA2418634A1 (en) 1998-11-12
NZ513881A (en) 2002-10-25
HUP0003330A2 (hu) 2001-05-28
EP1005342A1 (en) 2000-06-07
OA11169A (en) 2003-04-25
IL155799A0 (en) 2003-12-23
GEP20032970B (en) 2003-05-27
BG109365A (en) 2006-08-31
AU740022B2 (en) 2001-10-25
EP1222921A1 (en) 2002-07-17
EP1005342A4 (en) 2001-02-07
EA199901012A1 (ru) 2000-08-28
EE04870B1 (et) 2007-08-15
NZ500149A (en) 2001-11-30
SK151199A3 (en) 2000-07-11
CZ298269B6 (cs) 2007-08-08
PL336805A1 (en) 2000-07-17
NO20021832L (no) 2000-01-04
IS5223A (is) 1999-10-19
CN1552322A (zh) 2004-12-08
CZ391199A3 (cs) 2000-07-12
AP9901675A0 (en) 1999-12-31
CA2418634C (en) 2004-10-26
AP1103A (en) 2002-09-04
EE9900578A (et) 2000-08-15
ME00530B (me) 2011-10-10
HU229641B1 (en) 2014-03-28
RO120605B1 (ro) 2006-05-30
DE69809928D1 (de) 2003-01-16
SI20149A (sl) 2000-08-31
DK1005342T3 (da) 2003-03-24
PL193275B1 (pl) 2007-01-31
LV12492B (en) 2001-01-20
KR100426657B1 (ko) 2004-04-13
UA74388C2 (uk) 2005-12-15
AU7289598A (en) 1998-11-27
EA002920B1 (ru) 2002-10-31
NO20021832D0 (no) 2002-04-18
SK283946B6 (sk) 2004-05-04
BG103958A (en) 2000-07-31
CA2288003C (en) 2003-10-21
UA57079C2 (uk) 2003-06-16
IS2087B (is) 2006-03-15
DE69827417T2 (de) 2005-10-27
SI20149B (en) 2001-08-31
ES2150404T3 (es) 2003-07-01
JP3739802B2 (ja) 2006-01-25
EA200100956A1 (ru) 2002-02-28
NO335781B1 (no) 2015-02-16
TR199902733T2 (xx) 2000-03-21
HK1025907A1 (en) 2000-12-01
DE69809928T2 (de) 2003-04-24
BR9808722A (pt) 2000-07-11
NO995406L (no) 2000-01-04
KR20010020322A (ko) 2001-03-15
LV12492A (en) 2000-06-20
IL132516A (en) 2003-12-10
CZ298270B6 (cs) 2007-08-08
ATE228839T1 (de) 2002-12-15
IL155799A (en) 2004-08-31
WO1998050035A1 (en) 1998-11-12
AR057242A2 (es) 2007-11-21
CA2288003A1 (en) 1998-11-12
PT1222921E (pt) 2005-02-28
CN1158074C (zh) 2004-07-21
ATE281166T1 (de) 2004-11-15
JP2001503067A (ja) 2001-03-06
KR100576646B1 (ko) 2006-05-08
BG64973B1 (bg) 2006-11-30
SK283947B6 (sk) 2004-05-04
CN1255060A (zh) 2000-05-31
HUP0003330A3 (en) 2002-10-28
NO995406D0 (no) 1999-11-04

Similar Documents

Publication Publication Date Title
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
GT199900203A (es) Composiciones de celecoxib.
BR9810495A (pt) Composição farmacêutica
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
MY129356A (en) Electrospun pharmaceutical compositions
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
DE69917796D1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
ECSP003685A (es) Formulaciones orales de liberacion controlada
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica